Group One Trading’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $38.1K | Sell |
3,800
-42,300
| -92% | -$391K | ﹤0.01% | 5440 |
|
|
2026
Q2 | $386K | Sell |
46,100
-9,900
| -18% | -$90.2K | ﹤0.01% | 3741 |
|
|
2026
Q1 | $505K | Buy |
56,000
+15,600
| +39% | +$246K | ﹤0.01% | 3341 |
|
|
2025
Q4 | $737K | Sell |
40,400
-82,700
| -67% | -$1.39M | ﹤0.01% | 3169 |
|
|
2025
Q3 | $1.8M | Buy |
123,100
+66,800
| +119% | +$1.15M | ﹤0.01% | 2422 |
|
|
2025
Q2 | $1.03M | Buy |
56,300
+11,500
| +26% | +$235K | ﹤0.01% | 2737 |
|
|
2025
Q1 | $889K | Buy |
44,800
+5,800
| +15% | +$100K | ﹤0.01% | 2558 |
|
|
2024
Q4 | $669K | Buy |
39,000
+22,900
| +142% | +$431K | ﹤0.01% | 2933 |
|
|
2024
Q3 | $322K | Sell |
16,100
-1,300
| -7% | -$20.2K | ﹤0.01% | 3206 |
|
|
2024
Q2 | $195K | Buy |
17,400
+16,900
| +3,380% | +$142K | ﹤0.01% | 3410 |
|
|
2024
Q1 | $3.3K | Buy |
+500
| New | +$2.73K | ﹤0.01% | 6340 |
|
|
2023
Q4 | – | Sell |
-11,500
| Closed | -$41.2K | – | 7293 |
|
|
2023
Q3 | $41.2K | Sell |
11,500
-44,400
| -79% | -$171K | ﹤0.01% | 5284 |
|
|
2023
Q2 | $206K | Buy |
55,900
+9,600
| +21% | +$35.6K | ﹤0.01% | 3896 |
|
|
2023
Q1 | $153K | Sell |
46,300
-33,700
| -42% | -$116K | ﹤0.01% | 3905 |
|
|
2022
Q4 | $310K | Sell |
80,000
-30,800
| -28% | -$95K | ﹤0.01% | 3466 |
|
|
2022
Q3 | $269K | Buy |
110,800
+47,500
| +75% | +$114K | ﹤0.01% | 3854 |
|
|
2022
Q2 | $125K | Buy |
63,300
+46,100
| +268% | +$90.7K | ﹤0.01% | 4768 |
|
|
2022
Q1 | $31K | Sell |
17,200
-773,600
| -98% | -$1.21M | ﹤0.01% | 6447 |
|
|
2021
Q4 | $1.12M | Buy |
790,800
+52,200
| +7% | +$68.6K | ﹤0.01% | 3246 |
|
|
2021
Q3 | $835K | Sell |
738,600
-219,900
| -23% | -$308K | ﹤0.01% | 3608 |
|
|
2021
Q2 | $1.53M | Buy |
958,500
+47,700
| +5% | +$83.9K | ﹤0.01% | 2919 |
|
|
2021
Q1 | $1.6M | Buy |
910,800
+418,800
| +85% | +$959K | ﹤0.01% | 2706 |
|
|
2020
Q4 | $959K | Buy |
492,000
+104,500
| +27% | +$220K | ﹤0.01% | 2673 |
|
|
2020
Q3 | $926K | Buy |
387,500
+158,100
| +69% | +$434K | ﹤0.01% | 2268 |
|
|
2020
Q2 | $672K | Buy |
229,400
+7,000
| +3% | +$20.1K | ﹤0.01% | 2377 |
|
|
2020
Q1 | $641K | Buy |
+222,400
| New | +$769K | 0.01% | 1867 |
|
|
2019
Q4 | – | Sell |
-2,100
| Closed | -$9K | – | 5050 |
|
|
2019
Q3 | $9K | Sell |
2,100
-900
| -30% | -$3.76K | ﹤0.01% | 4614 |
|
|
2019
Q2 | $12K | Buy |
+3,000
| New | +$13.2K | ﹤0.01% | 4352 |
|
Other funds holding ADMA
Group One Trading's ADMA Position: Q3 2026 in Review
Group One Trading sold out of ADMA Biologics (ADMA) in Q3 2026, closing a stake of 5,911 shares — an estimated $54.7K sold.
Group One Trading first reported a position in ADMA in Q3 2018 and held it in 18 quarters. The position peaked at $3.49M in Q4 2025. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.
- Group One Trading reported no remaining ADMA Biologics position as of Q3 2026 after selling out during the quarter.
- Group One Trading sold 5,911 ADMA Biologics shares in Q3 2026, an estimated $54.7K.
- Group One Trading first reported a position in ADMA Biologics in Q3 2018 and held it in 18 quarters.
- Group One Trading's ADMA Biologics position peaked at $3.49M in Q4 2025.
- 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.
Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.